Article Text

PDF
SAT0112 Improvements in Patient-Reported Physical Function, Pain and Global Disease Activity in Patients with Rheumatoid Arthritis after Treatment with Nnc0109-0012 (Anti-IL-20 Mab) in a Phase 2A Trial
  1. L. Senolt1,
  2. B. B. Hansen2,
  3. M. Strandberg-Larsen2,
  4. E. Dokoupilova3
  1. 1Institute of Rheumatology, Prague, Czech Republic
  2. 2Novo Nordisk, Soborg, Denmark
  3. 3Medical Plus, Uherske Hradiste, Czech Republic

Abstract

Background NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to IL-20 and neutralises its activity. The primary endpoint in this multicentre, randomised, double-blind, placebo-controlled, parallel group trial (DAS28 response at Week 12) was achieved, as reported elsewhere.

Objectives To assess the effect of NNC0109-0012 on patient-reported outcomes, a secondary endpoint in this phase 2a proof-of-principle trial.

Methods 67 patients with active RA and inadequate responses to MTX were randomised to 12 once-weekly doses of 3mg/kg NNC0109-0012 (n=45) or placebo (n=22) and stable background MTX, and then followed for an additional 13 weeks. Of the 67 randomised patients 43 were Rheumatoid Factor [RF]- and anti-citrullinated peptide antibody [ACPA]-positive. Physical function was assessed by the Health Assessment Questionnaire – Disability Index (HAQ-DI). The level of pain and global disease activity were recorded by the patients on a 10 cm Visual Analogue Scale (VAS). All patient-reported outcomes were assessed weekly from baseline to week 12, and an additional 3 times in the 13 week follow-up period. A mixed-effects model repeated measures was fitted to the change from baseline for each of the patient-reported outcomes including treatment; time and interaction between treatment and time as fixed factors; baseline score and interaction between time and baseline score as continuous covariates and subject as random effect.

Results In RF- and ACPA-positive patients all patient-reported outcomes were significantly improved. Physical function was significantly improved after 12 and 25 weeks (-0.45, p=0.047; -0.47, p=0.022, respectively). After 12 and 25 weeks, NNC0109-0012 versus placebo significantly reduced pain (-3.0 cm, p<0.001; -2.9 cm, p<0.001, respectively) and global disease activity (-2.8 cm, p=0.002; -2.8 cm, p<0.001, respectively). For both pain and global disease activity the effects in the RF- and ACPA-positive patients were up to 2 fold larger versus placebo than was observed for the Full Analysis Set. For the Full Analysis Set, physical function was not significantly improved for NNC0109-0012 versus placebo after end of treatment at 12 weeks (-0.26, p=0.130). Pain was significantly reduced for NNC0109-0012 versus placebo with a mean difference of -1.5 cm (p=0.034) after 12 weeks and -1.3 cm (p=0.046) at week 25. Global disease activity was significantly lower for patients treated with NNC0109-0012 versus placebo with a mean difference of -1.7 cm (p=0.018) after 12 weeks, and was maintained through the follow-up period with a mean difference of -1.4 cm (p=0.031) at week 25.

Conclusions 12-weeks treatment with 3 mg/kg NNC0109-0012 effectively improved physical function, pain and global disease activity in RF- and ACPA-positive patients with RA on stable MTX. These improvements were clinically relevant and sustained when measured at the end of the 13 weeks follow-up.

Disclosure of Interest L. Senolt: None Declared, B. Hansen Employee of: Novo Nordisk, M. Strandberg-Larsen Employee of: Novo Nordisk, E. Dokoupilova: None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.